221 related articles for article (PubMed ID: 33284237)
1. Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Elinzano H; Toms S; Robison J; Mohler A; Carcieri A; Cielo D; Donnelly J; Disano D; Vatketich J; Baekey J; Sturtevant A; MacKinnon K; Wood R; Safran H
Am J Clin Oncol; 2021 Feb; 44(2):49-52. PubMed ID: 33284237
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G; Martínez-Sales V; Vila V; Balañá C; Pérez-Segura P; Vaz MA; Benavides M; Gallego O; Palomero I; Gil-Gil M; Fleitas T; Reche E
Anticancer Drugs; 2016 Feb; 27(2):133-7. PubMed ID: 26574999
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G; Balañá C; Gallego O; Iglesias L; Pérez P; García JL
Anticancer Drugs; 2014 Jul; 25(6):717-22. PubMed ID: 24322542
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
6. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
7. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Wendland M; Dipetrillo TA; Corn BW; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):880-4. PubMed ID: 23725999
[TBL] [Abstract][Full Text] [Related]
8. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
[TBL] [Abstract][Full Text] [Related]
10. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
13. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S; Schaub C; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Galldiks N; Weller J; Mack F; Tzaridis T; Bähr O; Seidel C; Schlegel U; Schmidt-Graf F; Rohde V; Borchers C; Tabatabai G; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Glas M; Herrlinger U
J Neurooncol; 2019 Sep; 144(3):501-509. PubMed ID: 31325144
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
Smith CJ; Bekaii-Saab TS; Cook KD; Eiring RA; Halfdanarson TR; Hanna M; Jin Z; Jochum JA; Ma WW; Mitchell JL; Pitot HC; Jatoi A
Pancreatology; 2021 Mar; 21(2):379-383. PubMed ID: 33468394
[TBL] [Abstract][Full Text] [Related]
15. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
[TBL] [Abstract][Full Text] [Related]
16. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
17. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
[TBL] [Abstract][Full Text] [Related]
20. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
